Personalized Psychiatry and Neurology

Advanced search

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Full Text:


The purpose of this review is to analyze approaches to the treatment of depressive and negative disorders in schizophrenia in terms of their level of efficacy and safety. Materials and Methods: A search was conducted for full-text articles published over the last 10 years in PubMed, Springer, Wiley Online Library, Taylor & Francis Online, APA PsycInfo, CORE, Science Direct, and eLIBRARY.RU databases. Several articles published previously to this period were also included into the review due to their high scientific value. Results: Our review suggests that antidepressants (ADs) are effective medications and they can be prescribed to correct depressive disorders and negative symptoms in patients with schizophrenia when used in combination with antipsychotics (АPs). However, when administering ADs and АPs combinations, it is important to consider the safety profile of these combinations as well as their tolerance. Negative symptoms of schizophrenia, including those induced by a number of АP, are less amenable to correction by АDs monotherapy, which requires a long period of АPs (on average - 8 weeks), which can be limited in the real life of the patient outside the hospital. Current approaches to the therapy of depressive disorders in patients suffering from schizophrenia vary from country to country. However, most of АDs used in clinical psychiatric practice are widely used in the comorbid state under consideration. Conclusion: The efficacy and safety of АDs of the different classes considered in this review depends on their mechanisms of action, duration of admission, type of АPs taken, and specific clinical situation (acute depressive disorder, major depressive episode, or chronic depressive episode). Most promising in clinical practice are serotonin–norepinephrine reuptake inhibitors (SNRIs) and dual ADs. The use of tricyclic antidepressants (TCAs) is limited due to a higher risk of adverse drug reactions (ADRs). The use of most selective serotonin reuptake inhibitors (SSRIs) is limited due to the risk of aggravation of hallucinations (this risk being higher for patients with visual hallucinations, and lower for those with auditory hallucinations) and\or iatrogenic psychosis. These ADRs may probably occur in patients suffering from schizophrenia due to their ideal "poor metabolizer" pharmacogenetic profile, since most of the drugs considered in this review have hepatic metabolism.

About the Authors

M. A. Novitsky
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation

Maxim A. Novitsky

3, Bekhterev str., 192019, Saint-Petersburg

A. De Sousa
Lokmanya Tilak Municipal Medical College; International Centre for Education and Research in Neuropsychiatry (ICERN), Samara State Medical University

Avinash De Sousa

400022, Mumbai, 

443079, Samara

A. R. Asadullin
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology Bashkir State Medical University
Russian Federation

Azat R. Asadullin

3, Bekhterev str., 192019, Saint-Petersburg, 

3, Lenin str., 450008, Ufa

O. A. Gavrilyuk
The Center of Collective Usage “Molecular and Cell Technologies”, V. F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation

Oksana A. Gavrilyuk

1, P. Zheleznyak str., 660022

A. V. Petrov
The Center of Collective Usage “Molecular and Cell Technologies”, V. F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation

Artem V. Petrov

1, P. Zheleznyak str., 660022

R. F. Nasyrova
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology International Centre for Education and Research in Neuropsychiatry (ICERN), Samara State Medical University
Russian Federation

Regina F. Nasyrova

3, Bekhterev str., 192019, Saint-Petersburg, 

443079, Samara


1. Van Os, J.; Kenis, G.; Rutten, B. The environment and schizophrenia. Nature 2010, 468, 203–212. doi: 10.1038/nature09563

2. Kaluev, A.V.; Demin, K.A.; Donbass, A.D. Genomic mechanisms of anxiety and depression pathogenesis in experimental models. Review of Psychiatry and Medical Psychology named after V.M. Bekhterev 2019, (4-1): 48-50. In Russian doi: 10.31363/2313-7053-2019-4-1-48-50

3. Addington, D.; Addington, J. Attempted suicide and depression in schizophrenia. Acta Psychiatrica Scandinavica 1992, 85:288-291.

4. Chemerinski, E.; Bowie, C.; Anderson, H.; Harvey, P.D. Depression in schizophrenia: methodological artifact or distinct feature of the illness? The Journal of Neuropsychiatry and Clinical Neurosciences 2008, 20(4), 431–440. doi: 10.1176/jnp.2008.20.4.431

5. Hicks, J.K.; Sangkuhl, K.; Swen, J.J.; Ellingrod, V.L.; Müller, D.J.; Shimoda, K.; Bishop, J.R.; Kharasch, E.D.; Skaar, T.C.; Gaedigk, A.; Dunnenberger, H.M.; Klein, T.E.; Caudle, K.E.; Stingl, J.C. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017, 102(1), 37-44. doi: 10.1002/cpt.597.

6. Kirchheiner, J.; Nickchen, K.; Bauer, M.; Wong, M.R.; Licinio, J.; Roots, I.; Brockmöller, J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 2004, 9, 442–473.

7. Vaiman, E.E.; Novitsky, M.A.; Nasyrova, R.F. Pharmacogenetics of chlorpromazine and its role in the development of antipsychotic-induced parkinsonism. Personalized Psychiatry and Neurology. 2021; 1(1): 11-17.

8. Abdyrakhmanova, A.K.; Shnayder, N.A.; Neznanov, N.G.; Nasyrova, R.F. Pharmacogenetics of quetiapine. Personalized Psychiatry and Neurology. 2021; 1(1): 73-83.

9. Nasyrova, R.F.; Shnayder, N.A.; Mironov, K.O.; Shipulin, G.A.; Dribnokhodova, O.P.; Golosov, E.A.; Tolmachev, M.Y.; Andreev, B.P. Pharmacogenetics of schizophrenia in real clinical practice: A clinical case. Neurology, Neuropsychiatry, Psychosomatics 2018, 10(4): 88-93. doi: 10.14412/2074-2711-2018-4-88-93

10. Han, C.; Wang, S.M.; Kato, M.; Lee, S.J.; Patkar, A.A.; Masand, P.S.; Pae, C.U. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013 ;13(7): 851-70. doi: 10.1586/14737175.2013.811901.

11. Wang, S.M.; Han, C.; Lee, S.J.; Jun, T.Y.; Patkar, A.A.; Masand, P.S.; Pae, C.U. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update [published correction appears in Chonnam Med J. 2019 Jan;55(1):73]. Chonnam Med J. 2016; 52(3): 159-172. doi:10.4068/cmj.2016.52.3.159

12. Ulrich, S.; Messer, T. Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence. Current Medical Research and Opinion 2021, 37(7): 1233-1248. doi: 10.1080/03007995.2021.1895095.

13. Kampling, H.; Baumeister, H.; Bengel, J.; Mittag, O. Prevention of depression in adults with long-term physical conditions. The Cochrane Database of Systematic Reviews 2021, 3(3). doi: 10.1002/14651858.CD011246.pub2.

14. Nussbaumer-Streit, B.; Thaler, K.; Chapman, A.; Probst, T.; Winkler, D.; Sönnichsen, A.; Gaynes, B.N.; Gartlehner, G. Second-generation antidepressants for treatment of seasonal affective disorder. The Cochrane Database of Systematic Reviews 2021, 3. doi: 10.1002/14651858.CD008591.pub3.

15. Wilson, M.; Tripp, J. Clomipramine. [Updated 2021 Jan 26]. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing 2021 Jan. Available from: PMID: 31082050.

16. Yang, Y.; Guangrong, Z.; Xiaojing, W.; Gu, W. Fine-tuning pharmacological properties of mirtazapine antidepressant drug: a theoretical study. Journal of Biomolecular Structure and Dynamics 2021, 9:1-9. doi: 10.1080/07391102.2021.1896386

17. Majeed, A.; Xiong, J.; Teopiz, K.M.; Ng, J.; Ho, R.; Rosenblat, J.D.; Phan, L.; Cao, B.; McIntyre, R.S. Efficacy of dextromethorphan for the treatment of depression: A systematic review of preclinical and clinical trials. Expert Opinion on Emerging Drugs 2021, 26(1):63-74. doi: 10.1080/14728214.2021.1898588.

18. Huecker, M.R.; Smiley, A.; Saadabadi, A. Bupropion. 2021 Apr 19. In: Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. PMID: 29262173.

19. Maeda, I.; Inoue, S.; Uemura, K.; Tanimukai, H.; Hatano, Y.; Yokomichi, N.; Amano, K.; Tagami, K.; Yoshiuchi, K.; Ogawa, A.; Iwase, S. Phase-r delirium study group. Low-dose trazodone for delirium in patients with cancer who received specialist palliative care: a multicenter prospective study. Journal of Palliative Medicine 2021, 24(6): 914-918. doi: 10.1089/jpm.2020.0610

20. Laban, T.S.; Saadabadi, A. Monoamine oxidase inhibitors (MAOI). National Center for Biotechnology Information, U.S. National Library of Medicine. Published April 7, 2019. Available from:

21. Baker, G.B.; Coutts, R.T.; McKenna, K.F.; Sherry-McKenna, R.L. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. Journal of Psychiatry and Neuroscience 1992, 17(5): 206-214. PMID: 1362653

22. Thomas, S.J.; Shin, M.; McInnis, M.G.; Bostwick, J.R. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy 2015, 35(4):433-49. doi: 10.1002/phar.1576.

23. Krishnan, K. Revisiting monoamine oxidase inhibitors. Journal of Clinical Psychiatry 2007, 68(8):35–41. PMID: 17640156

24. Hodgman, M.J.; Martin, T.G.; Krenzelok, E.P. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Human and experimental toxicology 1997, 16: 14–17. doi: 10.1177/0960327197016001031

25. Brubacher, J.R.; Hoffman, R.S.; Lurin, M.J. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Veterinary and Human Toxicology 1996, 38: 358–361. PMID: 8888541

26. Keltner, N.; Harris, C.P. Serotonin syndrome: a case of fatal SSRI/MAOI interaction. Perspectives in Psychiatric Care 1994, 30: 26–31. doi: 10.1111/j.1744-6163.1994.tb00446.x

27. Neuvonen, P.J.; Pohjola-Sintonen, S.; Tacke, U.; Vuori, E. Five fatal cases of serotonin syndrome after moclobemidecitalopram or moclobemide-clompiramine overdoses. The Lancet 1993, 342: 1419. doi: 10.1016/0140-6736(93)92774-n

28. Rapaport, M.H. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. The Journal of Clinical Psychiatry 2007, 68(8) :42–46. PMID: 17640157

29. Nierenberg, A.A.; Keck, P.E. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. Journal of Clinical Psychopharmacology 1989, 9: 42–45. PMID: 2708555

30. Jacobsen, F.M. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. The Journal of Clinical Psychiatry 1990, 51: 298–302; PMID: 2365668

31. Zetin, M. Combined use of trazodone and phenelzine in depression: case report. The Journal of Clinical Psychiatry 1984, 45: 182–183. PMID: 6715295

32. Ulrich, S.; Messer, T. Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence. Current Medical Research and Opinion 2021, 37(7): 1233-1248. doi: 10.1080/03007995.2021.1895095

33. Schiele, B.C. Treatment of pseudoneurotic schizophrenics and chronic neurotics. The Canadian Journal of Psychiatry 1962, 7: 60-66. doi: 10.1177/070674376200701s11.

34. Meyer, J.M.; Cummings, M.A.; Proctor, G. Augmentation of phenelzine with aripiprazole and quetiapine in a treatmentresistant patient with psychotic unipolar depression: case report and literature review. CNS Spectrums 2017, 22(5): 391-396. doi: 10.1017/S1092852916000821

35. Sokolski, K.N.; Brown, B.J. Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. Annals of Pharmacotherapy 2006, 40(3) :567-570. doi: 10.1345/aph.1G416

36. Tiller, J.W. The new antidepressants - clinical applications. Aust Prescr 1999; 22: 108-111

37. Silver, H.; Aharon, N.; Hausfater, N.; Jahjah, N. The effect of augmentation with moclobemide on symptoms of schizophrenia. Int Clin Psychopharmacol. 1999; 14(3): 193-195. PMID: 10435775

38. Bonnet, U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003; 9(1): 97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x

39. Fahy, T. Side effects of moclobemide in depressed patients refractory to other treatments. Irish Journal of Psychological Medicine 1993; 10(1), 24-27. doi:10.1017/S0790966700013264

40. Danilov, D.S. Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history. Neurology, Neuropsychiatry, Psychosomatics 2015, 1(7): 66-74. doi: 10.14412/2074-2711-2015-1-66-74

41. Buoli, M.; Serati, M.; Ciappolino, V.; Altamura, A.C. May selective serotonin reuptake inhibitors provide some benefit for the treatment of schizophrenia? Expert Opinion on Pharmacotherapy 2016, 17(10): 1375-1385. doi: 10.1080/14656566.2016.1186646.

42. Purgato, M.; Papola, D.; Gastaldon, C.; Trespidi, C.; Magni, L.R.; Rizzo, C.; Furukawa, T.A.; Watanabe, N.; Cipriani, A.; Barbui, C. Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2014, 3(4). doi: 10.1002/14651858.

43. Micheli, L.; Ceccarelli, M.; D'Andrea, G.; Tirone, F. Depression and adult neurogenesis: Positive effects of the antidepressant fluoxetine and of physical exercise. Brain Research Bulletin 2018, 143: 181-193. doi: 10.1016/j.brainresbull.2018.09.002.

44. Clinical psychopharmacogenetics, ed. by R.F. Nasyrova and N.G. Neznanov. - SPb: DEAN Publishing House, 2019, 405 p. ISBN 978-5-6043573-7-8.

45. Serretti, A.; Artioli, P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 2004, (4) 233– 244.

46. Kronenberg, S.; Frisch, A.; Rotberg, B.; Carmel, M.; Apter, A.; Weizman, A. Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics 2008; 9(11): 1725-1736. doi: 10.2217/14622416.9.11.1725.

47. Osis, L.; Bishop, J.R. Pharmacogenetics of SSRIs and sexual dysfunction. Pharmaceuticals 2010; 3(12): 3614-3628.

48. Fabbri, C.; Minarini, A.; Niitsu, T.; Serretti, A. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opin Drug Metab Toxicol 2014; 10(8): 1093-1118. doi: 10.1517/17425255.2014.928693

49. Cancelli, I.; Marcon, G.; Balestrieri, M. Factors associated with complex visual hallucinations during antidepressant treatment. Hum Psychopharmacol 2004 19(8): 577-584. doi: 10.1002/hup.640

50. Marcon, G.; Cancelli, I.; Zamarian, L.; Bergonzi, P.; Balestrieri, M. Visual hallucinations with sertraline. The Journal of Clinical Psychiatry 2004, 65(3): 446-447. doi: 10.4088/jcp.v65n0322f

51. Tripp, A.C.; Golden, S.A. Transient complex visual hallucinations with venlafaxine treatment: a case report. Prim Care Companion J Clin Psychiatry 2009; 11(2): 83. doi:10.4088/pcc.08l00647

52. Jacob, M.K.; Ash, P. Venlafaxine-induced complex visual hallucinations in a 17-year-old boy. J Clin Psychiatry 2009; 70(4): 601-603. doi: 10.4088/jcp.08l04627

53. Schuld, A.; Archelos, J.J.; Friess, E. Visual hallucinations and psychotic symptoms during treatment with selective serotonin reuptake inhibitors: is the sigma receptor involved? Journal of Clinical Psychopharmacology 2000, 20(5): 579-580. doi: 10.1097/00004714-200010000-00014

54. Safeekh, A.T.; Pinto, D. Venlafaxine-induced psychotic symptoms. Indian J Psychiatry 2009; 51(4): 308-309. doi: 10.4103/0019-5545.58301.

55. Cancelli, I.; Marcon, G.; Balestrieri, M. Factors associated with complex visual hallucinations during antidepressant treatment. Human Psychopharmacology Clinical and Experimental 2004, 19(8): 577-84. doi: 10.1002/hup.640

56. Monji, A.; Kato, T.; Mizoguchi, Y.; Horikawa, H.; Seki, Y.; Kanba, S. Visual and auditory hallucinations during normal use of paroxetine for treatment of major depressive disorder. The Journal of Neuropsychiatry and Clinical Neurosciences 2011, 23(4): 14-15. doi: 10.1176/jnp.23.4.jnpe14

57. Tanikawa, C.; Kamatani, Y.; Terao, C.; Usami, M.; Takahashi, A.; Momozawa, Y.; Suzuki, K.; Ogishima, S.; Shimizu, A.; Satoh, M.; Matsuo, K.; Mikami, H.; Naito, M.; Wakai, K.; Yamaji, T.; Sawada, N.; Iwasaki, M.; Tsugane, S.; Kohri, K.; Yu, A.S.L.; Yasui, T.; Murakami, Y.; Kubo, M.; Matsuda, K. Novel risk loci identified in a genome-wide association study of urolithiasis in a Japanese population. J Am Soc Nephrol 2019; 30(5): 855-864. doi: 10.1681/ASN.2018090942.

58. Capaldi, V.F.; Carr, R.B. Citalopram-induced hallucinations and delusions in a young adult. General Hospital Psychiatry 2010, 32(6): 648. e1-3. doi: 10.1016/j.genhosppsych.2010.07.008.

59. Mowla, A.; Khosravizadegan, F.; Ebrahimi, A.A.; Sabayan, B.; Pani, A. Citalopram associated with complex visual hallucination: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 30;33(3): 575-576. doi: 10.1016/j.pnpbp.2009.01.011.

60. Moorthy, S.; Arthur, P. Visual and auditory hallucinations associated with escitalopram in a young male. The Journal of Medical Research 2018; 4(6): 256-257. doi:10.31254/jmr.2018.4601

61. Waltereit, R.; Eifler, S.; Schirmbeck, F.; Zink, M. Visual and auditory hallucinations associated with citalopram treatment. Journal of Clinical Psychopharmacology 2013, 33(4): 583-584. doi: 10.1097/JCP.0b013e31829771ca

62. Taam, M.A.; de Boissieu, P.; Taam, R.A.; Breton, A.; Trenque T. Drug-induced hallucination: A case/non case study in the French Pharmacovigilance Database Eur. J. Psychiat. 2015, 29(1): 21-31. doi: 10.4321/S0213-61632015000100002

63. Fortunati, F.; Mazure, C.; Preda, A.; Wahl, R.; Bowers, M.Jr. Plasma catecholamine metabolites in antidepressantexacerbated mania and psychosis. Journal of Affective Disorders 2002, 68(2-3): 331-334. doi: 10.1016/s0165-0327(00)00327-x

64. Hayashi, T.; Su, T. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol 2005;3(4): 267-280. doi:10.2174/157015905774322516

65. Malik, M.; Rangel-Barajas, C.; Sumien, N.; Su, C.; Singh, M.; Chen, Z.; Huang, R.Q.; Meunier, J.; Maurice, T.; Mach, R.H.; Luedtke, R.R. The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice. Br J Pharmacol 2015 ; 172(10): 2519-2531. doi: 10.1111/bph.13076.

66. Penke, B.; Fulop, L.; Szucs, M.; Frecska, E. The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases. Curr Neuropharmacol 2018; 16(1) :97-116. doi:10.2174/1570159X15666170529104323.

67. Hunt, M.J.; Kopell, N.J.; Traub, R.D.; Whittington, M.A. Aberrant Network Activity in Schizophrenia. Trends Neurosci 2017; 40(6): 371-382. doi:10.1016/j.tins.2017.04.003

68. Schuld, A.; Archelos, J.J.; Friess, E. Visual hallucinations and psychotic symptoms during treatment with selective serotonin reuptake inhibitors: is the sigma receptor involved? J Clin Psychopharmacol 2000; 20(5): 579-80. doi: 10.1097/00004714-200010000-00014

69. Helfer, B.; Samara, M.T.; Huhn, M.; Klupp, E.; Leucht, C.; Zhu, Y.; Engel, R.R.; Leucht,aS. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-Analysis. American Journal of Psychiatry 2016, 1;173(9): 876-86. doi: 10.1176/appi.ajp.2016.15081035.

70. Buoli, M; Serati, M.; Ciappolino, V.; Altamura, A.C. May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia? Expert Opin Pharmacother 2016; 17(10): 1375-1385. doi: 10.1080/14656566.2016.1186646.

71. Drobizhev, M.Y. Selective serotonin and norepinephrine reuptake inhibitors. Psychiatry and Psychopharmacotherapy named after P.B. Gannushkin 2005, 4: 217-223.

72. Perahia, D.G.; Pritchett, Y.L.; Kajdasz, D.K.; Bauer, M.; Jain, R.; Russell, J.M.; Walker, D.J.; Spencer, K.A.; Froud, D.M.; Raskin, J.; Thase, M.E. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Journal of Psychiatric Research 2008, 42(1): 22-34. doi: 10.1016/j.jpsychires.2007.01.008.

73. Nemeroff, C.B.; Schatzberg, A.F.; Goldstein, D.J.; Detke, M.J.; Mallinckrodt, C.; Lu, Y.; Tran, P.V. Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin 2002, 36(4): 106-132. PMID: 12858150.

74. Nelson, J.C.; Pritchett. Y.L.; Martynov, O.; Yu J.Y.; Mallinckrodt, C.H.; Detke M,J. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Primary Care Companion to The Journal of Clinical Psychiatry 2006, 8(4): 212-219. doi: 10.4088/pcc.v08n0404.

75. Raskin, J.; Goldstein, D.J.; Mallinckrodt, C.H.; Ferguson, M.B. Duloxetine in the long-term treatment of major depressive disorder. The Journal of Clinical Psychiatry 2003, 64(10): 1237-1244. doi: 10.4088/jcp.v64n1015

76. Rickels, K.; Downing, R.; Schweizer, E.; Hassman, H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 1993, 50(11): 884-895. doi: 10.1001/archpsyc.1993.01820230054005.

77. Rudolph, R.L.; Entsuah, R.; Chitra, R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. Journal of Clinical Psychopharmacology 1998, 18(2): 136-144. doi: 10.1097/00004714-199804000-00006.

78. Raedler, T. J.; Jahn, H.; Arlt, J.; Kiefer, F.; Schick, M.; Naber, D.; & Wiedemann, K. Adjunctive use of reboxetine in schizophrenia. European Psychiatry 2004, 19(6), 366–369. doi: 10.1016/j.eurpsy.2004.06.017

79. Usall, J.; López-Carrilero, R.; Iniesta, R.; Roca, M.; Caballero, M.; Rodriguez-Jimenez, R.; Oliveira, C.; Bernardo, M.; Corripio, I.; Sindreu, S.D.; González Piqueras, J.C.; Felipe, A.E.; Fernandez de Corres, B.; Ibáñez, A.; Huerta, R.; Abordaje síntomas negativos esquizofrenia group. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. The Journal of Clinical Psychiatry 2014, 75(6): 608- 615. doi: 10.4088/JCP.13m08551. PMID: 25004184

80. Friedman, J.I.; Carpenter, D.; Lu, J.; Fan, J.; Tang, C.Y.; White, L.; Parrella, M.; Bowler, S.; Elbaz, Z.; Flanagan, L.; Harvey, P.D. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. Journal of Clinical Psychopharmacology 2008, 28(1): 59-63. doi: 10.1097/jcp.0b013e318161318f.

81. Shahzad, A.M.; Javed, Z.; & Kumar, A. Atomoxetine for schizophrenia. Cochrane Database of Systematic Reviews 2014. doi: 10.1002/14651858.cd011035

82. Solmi, M.; Fornaro, M.; Toyoshima, K.; Carvalho, A.F.; Köhler, C.A.; Veronese, N.; Stubbs, B.; de Bartolomeis, A.; Correll, C.U. Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. CNS Spectr 2019; 24(5): 479-495. doi: 10.1017/S1092852918001050

83. Štuhec, M.; Švab, V. Atomoxetine-induced life-threatening long QT syndrome. Ir J Med Sci 2013; 182: 535–537.

84. Purse, M. Overview of tricyclic antidepressants. Older-generation drugs still have their place in treatment: in Very Well Mind. Available: Updated on October 05.2020

85. Moraczewski J, Aedma KK. Tricyclic Antidepressants. [Updated 2020 Dec 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from:

86. Depression: How effective are antidepressants? National Center for Biotechnology Information. Updated Jan 12, 2017 Available:

87. Skarl S. Anxiety and Depression Association of America. Medication. Journal of Consumer Health on the Internet 2015, 19(2): 100-106. doi: 10.1080/15398285.2015.1035595

88. Bauer, M.; Pfennig, A.; Severus, E.; Weybrau, P.S.; Angst, J.; Müller, H-Yu. Clinical guidelines of the World Federation of Societies of Biological Psychiatry (WFPS) for Biological Therapy of Unipolar Depressive. Modern Therapy of Mental Disorders 2016 , 4: 33-39.

89. Shoja-Shefti, S. Effectiveness of bromocriptine, fluoxetine and nortriptyline in ameliorating the negative symptoms of schizophrenia. Current Psychopharmacology 2019, 5 (1 and 2): 58-63

90. Apiquian, R.; Ulloa, E.; Fresan, A.; Loyzaga, C.; Nicolini, H.; Kapur, S. Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. Schizophrenia Research 2003, 59(1): 35-9. doi: 10.1016/s0920-9964(01)00342-5. PMID: 12413640.

91. Mazeh, D.; Shahal, B.; Saraf, R.; Melamed, Y. Venlafaxine for the treatment of depressive episode during the course of schizophrenia. Journal of Clinical Psychopharmacology 2004, 24(6): 653-655. doi: 10.1097/

92. Steen, N.E.; Aas, M.; Simonsen, C.; Dieset, I.; Tesli, M.; Nerhus, M.; Gardsjord, E.; Mørch, R.; Agartz, I.; Melle, I.; Vaskinn, A.; Spigset, O.; Andreassen, O.A. Serum level of venlafaxine is associated with better memory in psychotic disorders. Schizophrenia Research 2015, 169(1-3): 386-392. doi: 10.1016/j.schres.2015.10.021.

93. Cardinal, R.N.; Savulich, G.; Mann, L.M.; Fernández-Egea, E. Association between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case register. NPJ Schizophrenia 2015, 21, 1:15035. doi: 10.1038/npjschz.2015

94. Nikbakhat, M.R.; Arabzadeh, S.; Zeinoddini, A.; Khalili, Z.; Rezaei, F.; Mohammadinejad, P.; Ghaleiha, A.; Akhondzadeh, S. Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Pharmacopsychiatry 2016, 49(4): 162-9. doi: 10.1055/s-0042-101557.

95. Mico, U.; Bruno, A.; Pandolfo, G.; Maria Romeo, V.; Mallamace, D.; D’Arrigo, C.; Muscatello, M. R. A. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia. International Clinical Psychopharmacology 2011, 26(6), 303– 310. doi: 10.1097/yic.0b013e32834bbc0d

96. Fava, M.; Papakostas, G.I.; Petersen, T.; Mahal, Y.; Quitkin, F.; Stewart, J.; McGrath, P. Switching to bupropion in fluoxetineresistant major depressive disorder. Annals of Clinical Psychiatry 2003, 15: 17–22.

97. Coryell W. Drug treatment of depression. in MSD Manual. Available: Updated on Mar 2020

98. Patel, K.; Allen, S.; Haque, M.N.; Angelescu, I.; Baumeister, D.; Tracy, D.K. Bupropion: a systematic review and metaanalysis of effectiveness as an antidepressant. Therapeutic Advances in Psychopharmacology 2016, 6(2): 99-144. doi: 10.1177/2045125316629071

99. Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960, 23(1): 56–62. doi: 10.1136/jnnp.23.1.56

100. Montgomery, S.A.; Asberg, M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979, 134: 382-389. doi: 10.1192/bjp.134.4.382.

101. Rush, A.J.; Giles, D.E.; Schlesser, M.A.; Fulton, C.L.; Weissenburger, J.; Burns, C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Research 1986, 18(1): 65-87. doi: 10.1016/0165-1781(86)90060-0.

102. Williams, J.B. A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry 1988, 45(8): 742-747. doi: 10.1001/archpsyc.1988.01800320058007

103. Brown, E.S.; Vornik, L.A.; Khan, D.A.; Rush, A.J. Bupropion in the treatment of outpatients with asthma and major depressive disorder. The International Journal of Psychiatry in Medicine 2007, 37(1): 23-28. doi: 10.2190/D235-2285-2121-6724.

104. Ferguson, J.; Cunningham, L.; Merideth, C.; Apter, J.; Feighner, J.; Ionescu-Pioggia, M.; Samara, B.; Johnston, J.A.; Ascher, J. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Annals of Clinical Psychiatry 1994, 6(3): 153-60. doi: 10.3109/10401239409148997.

105. Gross, P.K.; Nourse, R.; Wasser, T.E.; Bukenya, D. Safety and efficacy of bupropion extended release in treating a community sample of Hispanic and african american adults with major depressive disorder: an open-label study. Primary Care Companion to The Journal of Clinical Psychiatry 2007, 9(2): 108-12. doi: 10.4088/pcc.v09n0204.

106. Walker, P.W.; Cole, J.O.; Gardner, E.A.; Hughes, A.R.; Johnston, J.A.; Batey, S.R.; Lineberry, C.G. Improvement in fluoxetineassociated sexual dysfunction in patients switched to bupropion. The Journal of Clinical Psychiatry 1993, 54(12): 459-465. PMID: 8276736.

107. Tomarken, A.J.; Dichter, G.S.; Freid, C.; Addington, S.; Shelton, R.C. Assessing the effects of bupropion SR on mood dimensions of depression. Journal of Affective Disorders 2004, 78(3): 235-241. doi: 10.1016/S0165-0327(02)00306-3

108. Hewett, K.; Chrzanowski, W.; Schmitz, M.; Savela, A.; Milanova, V.; Gee, M.; Krishen, A.; Millen, L.; Leary, M.O.; Modell, J. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of Psychopharmacology 2009, 23(5): 531-538. doi: 10.1177/0269881108089602.

109. Hewett, K.; Gee, M.D.; Krishen, A.; Wunderlich, H.P.; Le Clus, A.; Evoniuk, G.; Modell, J.G. Double-blind, placebocontrolled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of Psychopharmacology 2010, 24(8): 1209-1216. doi: 10.1177/0269881109106953

110. Englisch, S.; Morgen, K.; Meyer-Lindenberg, A.; Zink, M. Risks and benefits of bupropion treatment in schizophrenia. Clinical Neuropharmacology 2013, 36(6): 203-215. doi: 10.1097/WNF.0b013e3182a8ea04

111. D’Agostino, A.; English, C.D.; Rey, J.A. Vortioxetine (Brintellix): a new serotonergic antidepressant. Drug Forecast P&T 2015, 40(1): 36–40. PMID: 25628505

112. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Stewart, J.W., Nierenberg, A.A.; Thase, M.E.; Ritz, L., Biggs, M.M., Warden D., Luther, J.F., Shores-Wilson, K., Niederehe, G., Fava, M. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. The New England Journal of Medicine 2006, 354(12): 1231-1242. doi: 10.1056/NEJMoa052963.

113. Santarsieri, D.; Schwartz, T.L. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context 2015; 4: 212-290. doi:10.7573/dic.212290

114. Purse, M. How reuptake inhibitor drugs work: in VeryWellMind. February 6 2021.

115. Perry, L.A.; Ramson, D.; Stricklin, S. Mirtazapine adjunct for people with schizophrenia. Cochrane Database of Systematic Reviews 2018, 5(5). doi: 10.1002/14651858.CD011943.pub2

116. Lee, J.; Cho, S.J.; Lee, K.S.; Yook, K.; Choe, A.Y.; Lee, S.; Kim, B.; Kim, K.H.; Choi, T.K.; Lee, S.H. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: a preliminary randomized placebo-controlled trial. Clinical Psychopharmacology and Neuroscience 2011, 9(2): 73-77. doi: 10.9758/cpn.2011.9.2.73

117. Abbasi, S.H.; Behpournia, H.; Ghoreshi, A.; Salehi, B.; Raznahan, M.; Rezazadeh, S.A.; Rezaei, F.; Akhondzadeh, S. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebocontrolled trial. Schizophrenia Research 2010, 116(2-3): 101-6. doi: 10.1016/j.schres.2009.11.008.

118. Mathew, K.A. Efficacy of mirtazapine as adjunct therapy to antipsychotics in the treatment of chronic schizophrenia. Australian Medical Student Journal 2015, Available:

119. Mutschler, J.; Rüsch, N.; Schönfelder, H.; Herwig, U.; Brühl, A.B.; Grosshans, M.; Rössler, W.; Russmann, H. Agomelatine for depression in schizophrenia: A Case-Series. Psychopharmacology Bulletin 2012, 45(1): 35-43. PMID: 27738367

120. Singh, S.; Singh, V.; Kar, N.; Chan, K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. British Journal of Psychiatry 2015, 197(3), 174-179. doi:10.1192/bjp.bp.109.067710.

121. Englisch, S.; Jung, H.S.; Lewien, A.; Becker, A.; Nowak, U.; Braun, H.; Thiem, J.; Eisenacher, S.; Meyer-Lindenberg, A.; Zink, M. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An OpenProspective Proof-of-Concept Study. Journal of Clinical Psychopharmacology 2016, 36(6): 597-607. doi: 10.1097/JCP.0000000000000587.

122. De Berardis, D.; Fornaro, M.; Serroni, N.; Campanella, D.; Rapini, G.; Olivieri, L.; Srinivasan, V.; Iasevoli, F.; Tomasetti, C.; De Bartolomeis, A.; Valchera, A.; Perna, G.; Mazza, M.; Di Nicola, M.; Martinotti, G.; Di Giannantonio, M. Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression. International Journal of Molecular Sciences 2015, 16, 1111-1130.

123. Mutschler, J.; Rüsch, N.; Schönfelder, H.; Herwig, U.; Brühl, B.A.; Grosshans, M.; Rössler, W. Agomelatine for Depression in Schizophrenia: A Case-Series. Psychopharmacology Bulletin 2012; 45(1): 35-43

124. Stuhec, M.; Oravecz, R. Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case. Wien Klin Wochenschr 2016; 128(7-8): 295-298. doi: 10.1007/s00508-015-0861-0.

125. Shiloh, R.; Zemishlany, Z.; Aizenberg, D.; Valevski, A.; Bodinger, L.; Munitz, H.; Weizman, A. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. International Clinical Psychopharmacology 2002, 17(2): 59-64. doi: 10.1097/00004850-200203000-00003.

126. Cowen, P.J. Psychopharmacology. In Comprehensive Clinical Psychology 1998. doi: 10.1016/B0080-4270(73)00248-0

127. Verbenko V.A., Aristov M.A. Pharmacological therapy of schizophrenia (modern view). Taurida Journal of Psychiatry 2015, 70 (1): 5-14.

128. Danilov, D.S.; Magomedova, D.O.; Matsneva, M.E. The rationale for antidepressants in the treatment of schizophrenia: A modern view on the problem in the context of evidence-based medicine. Neurology, Neuropsychiatry, Psychosomatics 2016, 8(1): 71-81. doi: 10.14412/2074-2711-2016-1-71-81

129. Millan, M.J.; Agid, Y.; Brüne, M.; Bullmore, E.T.; Carter, C.S.; Clayton, N.S.; Connor, R.; Davis, S.; Deakin, B.; DeRubeis, R.J.; Dubois, B.; Geyer, M.F.; Goodwin, G.M.; Gorwood, P.; Jay, T.M.; Joëls, M.; Mansuy, I.M.; Meyer-Lindenberg, A.; Murphy, D.; Rolls, E.; Saletu, B.; Spedding, M.; Sweeney, J.; Whittington, M.; Young, L.J. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery 2012, 11(2): 141-168. doi: 10.1038/nrd3628

130. Allain, H.; Lieury, A.; Brunet-Bourgin, F.; Mirabaud, C.; Trebon, P.; Le Coz, F.; Gandon, J.M. Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1992, 106: 56-61. doi: 10.1007/BF02246237

131. Chertkow, Y.; Weinreb, O.; Youdim, M.B.; Silver, H. Molecular mechanisms underlying synergistic effects of SSRIantipsychotic augmentation in treatment of negative symptoms in schizophrenia. Journal of Neural Transmission 2009, 116(11): 1529-1541. doi: 10.1007/s00702-009-0255-4

132. Harrison, P. Antidepressants have a role to play in schizophrenia. American Journal of Psychiatry 2016, Available:

133. Wang, P.; Si, T. Use of antipsychotics in the treatment of depressive disorders. Shanghai Arch Psychiatry 2013; 25(3): 134-140. doi:10.3969/j.issn.1002-0829.2013.03.002

134. Earley, W.; Guo, H.; Daniel, D.; Nasrallah, H.; Durgam, S.; Zhong, Y.; Patel, M.; Barabássy, Á.; Szatmári, B.; Németh, G. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res 2019; 204:282-288. doi: 10.1016/j.schres.2018.08.020

135. Andrusenko, M.P.; Morozova, M.A. A combination of antidepressants and neuroleptics in the treatment of affective disorders and schizophrenia: indications, side effects and complications. Journal of Neurology and Psychiatry named after S.S. Korsakova 2000, 100(11): 60-65. PMID: 11247192

136. Dunner, D.L.; Amsterdam, J.D.; Shelton, R.C.; Loebel, A.; Romano, S.J. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007; 68(7):1071–1077

137. Barbee, J.G.; Conrad, E.J.; Jamhour, N.J. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004; 65(7): 975–981.

138. Usov, G.M. Second generation antipsychotics in acute and long-term treatment of schizophrenia: a critical review of scientific data. Therapy of Mental Disorders 2020, 4: 28–35. doi: 10.21265/PSYPH.2020.94.92.004

139. Štuhec, M. Solifenacin-induced delirium and hallucinations. General Hospital Psychiatry 2013, 35(6): 682.e3-4. doi: 10.1016/j.genhosppsych.2013.06.002.

140. Štuhec, M.; Potočin, I.; Stepan, D.; Ušaj, L.; Petek, S.M.; Beović, B. Potential drug interactions with antibacterials in longterm care facilities analyzed by two interaction checkers. International Journal of Clinical Pharmacy 2019, 41(4):932-938. doi: 10.1007/s11096-019-00855-x.

For citation:

Novitsky M.A., De Sousa A., Asadullin A.R., Gavrilyuk O.A., Petrov A.V., Nasyrova R.F. Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia. Personalized Psychiatry and Neurology. 2021;1(2):21-45.

Views: 107

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2712-9179 (Online)